OMTX705 + Gemcitabine/Nab-Paclitaxel + Tislelizumab for Pancreatic Cancer

This trial explores a new treatment mix for individuals with advanced pancreatic cancer. It tests OMTX705, a drug targeting specific proteins in cancer cells, combined with existing drugs like gemcitabine, nab-paclitaxel (a chemotherapy drug), and tislelizumab (an immunotherapy drug). The trial seeks to determine the safest dose and assess how well the treatments work together. Individuals with pancreatic ductal adenocarcinoma (PDAC) that has progressed or cannot be surgically removed, and who have tried up to one other treatment option, might be suitable candidates. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new drug.

The trial requires that you stop taking medications that are strong inhibitors or inducers of certain liver enzymes (CYP3A4, 2D6, 1A2, 2C9, 2B6, and 2C19) at least 14 days before the first dose. If you're on these medications, you will need to stop them before participating.

Previous studies have shown that the combination of gemcitabine and nab-paclitaxel is generally safe for patients with pancreatic cancer. These studies confirmed that this combination works well and is usually manageable for patients in real-life settings, with most experiencing the treatment without severe side effects.

Research in animals has shown promising results for OMTX705, with significant slowing of tumor growth. However, this trial is among the first tests in humans, so information on its safety in people is limited. These early tests are crucial to assess patient tolerance.

Tislelizumab, another part of the trial, is also undergoing testing in other early studies to evaluate its safety. Researchers are examining its effects when used with the other drugs.

Researchers are excited about these treatments because they combine innovative approaches with standard chemotherapy to tackle pancreatic cancer more effectively. OMTX705 is a novel agent that may work synergistically with existing drugs like gemcitabine and nab-paclitaxel, potentially enhancing their anticancer effects. Additionally, the inclusion of tislelizumab, an immune checkpoint inhibitor, offers a unique mechanism by enabling the immune system to better recognize and attack cancer cells. This combination approach might offer superior outcomes compared to the standard chemotherapy options alone, making it a promising direction for future pancreatic cancer treatments.

Research shows that OMTX705, a new treatment, may aid in fighting pancreatic cancer. This trial involves participants receiving different treatment combinations. In some arms, OMTX705 is combined with nab-paclitaxel and gemcitabine, which have already been shown to extend patient survival compared to gemcitabine alone. In other arms, OMTX705 is combined with nab-paclitaxel, gemcitabine, and tislelizumab, a drug that enhances the immune system to combat cancer. Early signs suggest that adding tislelizumab might be beneficial. Although more research is needed, these combination treatments could offer new hope for individuals with advanced pancreatic cancer.¹⁶⁷⁸⁹